News | December 26, 2023
Astellas completes acquisition of Propella Therapeutics
Astellas has acquired abiraterone decanoate being developed by Propella to treat prostate cancer
Astellas has acquired abiraterone decanoate being developed by Propella to treat prostate cancer
Funding round led by Sarissa Capital, includes Sun Pharma, Polaris Partners
Transaction delivers KarXT, a first-in-class M1/ M4 muscarinic receptor agonist with differentiated efficacy and safety
If approved, patritumab deruxtecan would be a first-in-class HER3 directed DXd antibody drug conjugate for these patients
KBR will provide outreach, education and data analytics to support critical neuroscience research for the prevention and treatment of military members with CTE
Trastuzumab deruxtecan (Enhertu) is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer
V116 is an investigational, 21-valent pneumococcal conjugate vaccine specifically designed to protect adults
Studies have demonstrated that ZYIL1 is highly potent and can suppress inflammation caused by NLRP3 inflammasome activation
Darunavir is a protease inhibitor antiviral medicine that prevents Human Immunodeficiency Virus (HIV-1) from multiplying in the body
Expands patient reach to remotest towns by furthering investment in GoApptiv
Subscribe To Our Newsletter & Stay Updated
